Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXSCEL: Exenatide Once Weekly and Cardiovascular Outcomes in Type 2 Diabetes Mellitus
2010-021069-63Phase 3Completed
- Sponsor
- Amylin Pharmaceuticals
- Start
- Dec 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide Once Weekly + usual care with Placebo + usual care (2 arms). Started Dec 2010; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-021069-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021069-63.